Find in Library
Search millions of books, articles, and more
Indexed Open Access Databases
Later-Line Treatment with Lorlatinib in <i>ALK</i>- and <i>ROS1</i>-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis
oleh: Maximilian J. Hochmair, Hannah Fabikan, Oliver Illini, Christoph Weinlinger, Ulrike Setinek, Dagmar Krenbek, Helmut Prosch, Markus Rauter, Michael Schumacher, Ewald Wöll, Romana Wass, Elmar Brehm, Gudrun Absenger, Tatjana Bundalo, Peter Errhalt, Matthias Urban, Arschang Valipour
Format: | Article |
---|---|
Diterbitkan: | MDPI AG 2020-11-01 |
Deskripsi
In clinical practice, patients with <i>anaplastic lymphoma kinase (ALK)</i>-rearrangement–positive non–small-cell lung cancer commonly receive sequential treatment with ALK tyrosine kinase inhibitors. The third-generation agent lorlatinib has been shown to inhibit a wide range of <i>ALK</i> resistance mutations and thus offers potential benefit in later lines, although real-world data are lacking. This multicenter study retrospectively investigated later-line, real-world use of lorlatinib in patients with advanced <i>ALK</i>- or <i>ROS1</i>-positive lung cancer. Fifty-one patients registered in a compassionate use program in Austria, who received second- or later-line lorlatinib between January 2016 and May 2020, were included in this retrospective real-world data analysis. Median follow-up was 25.3 months. Median time of lorlatinib treatment was 4.4 months for <i>ALK</i>-positive and 12.2 months for <i>ROS</i>-positive patients. <i>ALK</i>-positive patients showed a response rate of 43.2%, while 85.7% percent of the <i>ROS1</i>-positive patients were considered responders. Median overall survival from lorlatinib initiation was 10.2 and 20.0 months for the <i>ALK</i>- and <i>ROS1</i>-positive groups, respectively. In the <i>ALK</i>-positive group, lorlatinib proved efficacy after both brigatinib and alectinib. Lorlatinib treatment was well tolerated. Later-line lorlatinib treatment can induce sustained responses in patients with advanced <i>ALK</i>- and <i>ROS1</i>-positive lung cancer.